Amber Therapeutics’ Series A wasn’t just a headline—it was a milestone. In one of the largest European Series A medtech financings to date, the company raised $100M to advance its closed-loop neuromodulation therapy for mixed urinary incontinence. Originally published here: https://www.lsieuropesummit.com/news/amber-therapeutics-series-a-behind-the-100m-raise